EyeBio

Merck & Co. ’s HPV vaccine Gardasil appears headed into a sales slump in China, and the country’s ongoing crackdown on corruption in healthcare could be a factor in the decline. Gardasil is the firm’s

Merck & Co., Inc. reported strong overall revenue growth for the second quarter of 2024 on 30 July, but the company’s second-biggest seller fell short of analyst consensus due to an unexpected sales

After a strong start to biopharma merger-and-acquisition activity in the first quarter of 2024, transactions declined notably in the second quarter, according to data provided by Evaluate. The second

In its Beyond Borders 2024 report, issued in tandem with the start of this year’s BIO International Convention, EY analysts said the biopharmaceutical industry appeared to turn a corner in late 2023